Schroder Investment Management Group Grows Stake in IDEXX Laboratories, Inc. (IDXX)

Share on StockTwits

Schroder Investment Management Group lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 97.9% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 110,276 shares of the company’s stock after acquiring an additional 54,555 shares during the period. Schroder Investment Management Group’s holdings in IDEXX Laboratories were worth $23,982,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at about $134,000. Cerebellum GP LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at about $181,000. Financial Gravity Wealth Inc. acquired a new position in IDEXX Laboratories in the 1st quarter valued at about $191,000. TLP Group LLC raised its stake in IDEXX Laboratories by 52,750.0% in the 1st quarter. TLP Group LLC now owns 1,057 shares of the company’s stock valued at $202,000 after purchasing an additional 1,055 shares during the last quarter. Finally, Winthrop Advisory Group LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at about $206,000. 91.22% of the stock is owned by institutional investors and hedge funds.

IDXX opened at $222.42 on Friday. The company has a debt-to-equity ratio of -14.77, a current ratio of 0.96 and a quick ratio of 0.73. The stock has a market capitalization of $21.62 billion, a price-to-earnings ratio of 67.81, a price-to-earnings-growth ratio of 2.28 and a beta of 0.64. IDEXX Laboratories, Inc. has a 12 month low of $146.09 and a 12 month high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Wednesday, August 1st. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.17 by $0.06. The company had revenue of $580.75 million during the quarter, compared to analysts’ expectations of $574.68 million. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The firm’s revenue was up 14.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.87 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 4.18 EPS for the current fiscal year.

In other news, insider Michael Lane sold 5,912 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $243.78, for a total transaction of $1,441,227.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce L. Claflin bought 415 shares of the firm’s stock in a transaction dated Friday, August 3rd. The shares were purchased at an average price of $242.12 per share, with a total value of $100,479.80. Following the acquisition, the director now directly owns 1,415 shares in the company, valued at approximately $342,599.80. The disclosure for this purchase can be found here. Insiders sold a total of 70,129 shares of company stock valued at $17,159,219 in the last 90 days. 2.56% of the stock is owned by company insiders.

Several brokerages recently weighed in on IDXX. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, August 6th. Credit Suisse Group lifted their price target on IDEXX Laboratories from $228.00 to $231.00 and gave the company an “outperform” rating in a report on Thursday, June 21st. BidaskClub cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Piper Jaffray Companies lifted their price target on IDEXX Laboratories to $236.00 and gave the company an “overweight” rating in a report on Wednesday, August 1st. Finally, Stifel Nicolaus lifted their price target on IDEXX Laboratories from $225.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, July 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $244.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: Using the New Google Finance Tool

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply